Is evantumumab/Carestream a targeted or immune drug?

Amivantamab (amivantamab) is a new type of bispecific antibody drug. Its mechanism of action has the characteristics of both targeted therapy and immunotherapy, so its classification is closer to the "targeted + immune fusion" treatment model. It was originally designed to simultaneously identify and combine two key receptor pathways, EGFR and MET. This dual blocking method can overcome some drug resistance problems, especially in non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. It shows unique therapeutic advantages.

As a targeted drug, evantumumab can block signaling pathways and inhibit the proliferation and survival of tumor cells by specifically bindingEGFR and MET receptors. This precise attack method makes it different from traditional chemotherapy drugs and reduces the extensive damage to normal cells. In a sense, it continues the idea of u200bu200bsmall molecule tyrosine kinase inhibitors (TKIs) to precisely inhibit mutant proteins, but uses an antibody form to make the drug distribution and mechanism of action more unique.

On the other hand, evantumumab also exhibits characteristics of immunotherapy. As an IgG1 type monoclonal antibody, it can not only block signaling pathways, but also activate the immune system through antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADCP), promoting the body's immune cells to recognize and eliminate tumors. This means that its efficacy does not only come from the inhibition of a single target, but achieves anti-cancer effects through multiple mechanisms.

Therefore, from the perspective of drug positioning, evantumumab is both a targeted drug and a part of immunotherapy. Its innovative structure of "bispecific antibody" makes it one of the representatives of the fusion of two major treatment ideas. Different from simple PD-1/PD-L1 immune checkpoint inhibitors, it emphasizes the combination of precise targeting and immune effects, which is also an important reason for its breakthrough in EGFR mutant lung cancer.

Reference materials:https://www.rybrevant.com/